🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchOrforglipron ATTAIN-4 — cardiovascular outcomes arm Page 5

Orforglipron ATTAIN-4 — cardiovascular outcomes arm

TrialTracker_MD Mon, May 25, 2026 at 7:53 AM 21 replies 544 viewsPage 5 of 5
JakeBK_lifts
Member
523
2,345
Jul 2024
Brooklyn, NY
May 30, 2026 at 11:12 PM#21
DoseLogDan said:
Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a…

True, with the qualification that this is a self-selected group. The people for whom it did not work post less, and that shapes everything we think we know.

1 1TrialTracker_MD
Reply Quote Save Share Report
Dr.PainCLE
Senior Member
1,234
6,234
Mar 2024
Cleveland, OH
Jun 1, 2026 at 10:20 PM#22
DoseLogDan said:
Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a…

This answered a question I did not know how to ask. Printing the relevant bit and taking it with me.

Last edited: Jun 2, 2026 at 1:20 AM
50 0tane_welly, Dr.PathRoch, mona_PHX and 47 others
Reply Quote Save Share Report
Dr.RheumBOS
Member
567
2,345
Apr 2024
Boston, MA
Jun 3, 2026 at 9:29 PM#23

From the other side of the consultation, briefly. If two explanations both fit, the useful question is which one predicts something the other does not. That is answerable; arguing about which sounds more plausible is not.

Worth separating that from cardiovascular outcomes, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

Ask again with the specifics and you will get a better answer than this one.

49 24cory_ATX, lori_vegas, Dr.PulmRoch and 46 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
Dr.GutHealth
Senior Member
1,456
7,890
Mar 2024
Minnesota
Jun 5, 2026 at 8:39 PM#24
Dr.RheumBOS said:
If two explanations both fit, the useful question is which one predicts something the other does not.

Same experience, arrived at from the opposite direction. The detail I would add is minor and it is already implied above.

48 23Dr.RaviCardio, jennifer_SEA, tyler_CSCS and 45 others
Reply Quote Save Share Report
RickReta_CO
Member
312
1,234
Jan 2025
Colorado
Jun 7, 2026 at 7:50 PM#25
Dr.RheumBOS said:
If two explanations both fit, the useful question is which one predicts something the other does not.

Coming at Dr.RheumBOS’s question from a different direction. The version of this that has an answer is narrower than the version being asked. Narrow it and it becomes tractable; leave it broad and the thread will produce nine confident and incompatible replies.

Last edited: Jun 8, 2026 at 12:50 AM
47 22LindaRN_retired, tommy_boulder, hyun_seoul and 44 others
Reply Quote Save Share Report
1345

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register